Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kirstine Jacobsen"'
Autor:
Qingqing Wu, Xiaoyang Luo, Mikkel G. Terp, Qingrun Li, Yuan Li, Lei Shen, Ying Chen, Kirstine Jacobsen, Trever G. Bivona, Haiquan Chen, Rong Zeng, Henrik J. Ditzel
Publikováno v:
Molecular Cancer, Vol 20, Iss 1, Pp 1-17 (2021)
Abstract Background Early recurrence is a major obstacle to prolonged postoperative survival in squamous cell lung carcinoma (SqCLC). The molecular mechanisms underlying early SqCLC recurrence remain unclear, and effective prognostic biomarkers for p
Externí odkaz:
https://doaj.org/article/94efa7580bc1461fa9dcc21496d26a26
Autor:
Mikkel G. Terp, Kirstine Jacobsen, Miguel Angel Molina, Niki Karachaliou, Hans C. Beck, Jordi Bertran-Alamillo, Ana Giménez-Capitán, Andrés F. Cardona, Rafael Rosell, Henrik J. Ditzel
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-13 (2021)
Abstract EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients is inevitable. Identification of resistance mechanisms and corresponding targeting strategies can lead to more successful later-line treatment in
Externí odkaz:
https://doaj.org/article/4079b23b742f40d7b05c71931a377a85
Autor:
Gro V. Røsland, Sissel E. Dyrstad, Deusdedit Tusubira, Reham Helwa, Tuan Zea Tan, Maria L. Lotsberg, Ina K. N. Pettersen, Anna Berg, Charlotte Kindt, Fredrik Hoel, Kirstine Jacobsen, Ari J. Arason, Agnete S. T. Engelsen, Henrik J. Ditzel, Per E. Lønning, Camilla Krakstad, Jean P. Thiery, James B. Lorens, Stian Knappskog, Karl J. Tronstad
Publikováno v:
Cancer & Metabolism, Vol 7, Iss 1, Pp 1-18 (2019)
Abstract Background Epithelial to mesenchymal transition (EMT) is a well-characterized process of cell plasticity that may involve metabolic rewiring. In cancer, EMT is associated with malignant progression, tumor heterogeneity, and therapy resistanc
Externí odkaz:
https://doaj.org/article/34446e854aaf4dda922810b5f57564ec
Autor:
Kirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, Cristina Teixidó, Niki Karachaliou, Martin Haar Pedersen, Josep Castellví, Mónica Garzón, Carles Codony-Servat, Jordi Codony-Servat, Ana Giménez-Capitán, Ana Drozdowskyj, Santiago Viteri, Martin R. Larsen, Ulrik Lassen, Enriqueta Felip, Trever G. Bivona, Henrik J. Ditzel, Rafael Rosell
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyrosine kinase inhibitor treatment. In this study, the authors show that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergi
Externí odkaz:
https://doaj.org/article/a117794eb5cd402d8bf7134ca915cc6e
Autor:
Henrik J. Ditzel, Mikkel G. Terp, Andrés Felipe Cardona, Jordi Bertran-Alamillo, Niki Karachaliou, Kirstine Jacobsen, Miguel Angel Molina, Ana Giménez-Capitán, Hans Christian Beck, Rafael Rosell
Publikováno v:
Terp, M G, Jacobsen, K, Molina, M A, Karachaliou, N, Beck, H C, Bertran-Alamillo, J, Giménez-Capitán, A, Cardona, A F, Rosell, R & Ditzel, H J 2021, ' Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells ', n p j Precision Oncology, vol. 5, no. 1, 65 . https://doi.org/10.1038/s41698-021-00208-w
npj Precision Oncology, Vol 5, Iss 1, Pp 1-13 (2021)
NPJ Precision Oncology
npj Precision Oncology, Vol 5, Iss 1, Pp 1-13 (2021)
NPJ Precision Oncology
EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients is inevitable. Identification of resistance mechanisms and corresponding targeting strategies can lead to more successful later-line treatment in many pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c46c82abe42d1054af287db1ac068689
https://findresearcher.sdu.dk:8443/ws/files/193451661/s41698_021_00208_w.pdf
https://findresearcher.sdu.dk:8443/ws/files/193451661/s41698_021_00208_w.pdf
Autor:
Mikkel G. Terp, Xiaoyang Luo, Henrik J. Ditzel, Rong Zeng, Ying Chen, Haiquan Chen, Qingrun Li, Lei Shen, Yuan Li, Qingqing Wu, Trever G. Bivona, Kirstine Jacobsen
Publikováno v:
Wu, Q, Luo, X, Terp, M G, Li, Q, Li, Y, Shen, L, Chen, Y, Jacobsen, K, Bivona, T G, Chen, H, Zeng, R & Ditzel, H J 2021, ' DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma ', Molecular Cancer, vol. 20, 108 . https://doi.org/10.1186/s12943-021-01403-w
Molecular Cancer, Vol 20, Iss 1, Pp 1-17 (2021)
Molecular Cancer
Molecular Cancer, Vol 20, Iss 1, Pp 1-17 (2021)
Molecular Cancer
Background Early recurrence is a major obstacle to prolonged postoperative survival in squamous cell lung carcinoma (SqCLC). The molecular mechanisms underlying early SqCLC recurrence remain unclear, and effective prognostic biomarkers for predicting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c456d8e0b7a81e32bd794453b1693e29
https://findresearcher.sdu.dk:8443/ws/files/191355244/s12943_021_01403_w.pdf
https://findresearcher.sdu.dk:8443/ws/files/191355244/s12943_021_01403_w.pdf
Autor:
Tuan Zea Tan, Henrik J. Ditzel, Olav Karsten Vintermyr, Agnete S.T. Engelsen, Maria Lie Lotsberg, David Micklem, Muntequa Ishtiaq Siraji, John D. Minna, Gro Gausdal, Lars A. Akslen, Laura Trachsel-Moncho, Austin Rayford, Kirstine Jacobsen, Ning Lu, Bruce C. Baguley, James B. Lorens, Salem Chouaib, Monica Hellesøy, Stéphane Terry, Anne Simonsen, Trever G. Bivona, Rolf A. Brekken, Gro V. Røsland, Katarzyna Wnuk-Lipinska, Jean Paul Thiery
Publikováno v:
Journal of Thoracic Oncology
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2020, 15, pp.973-999. ⟨10.1016/j.jtho.2020.01.015⟩
Lotsberg, M L, Wnuk-Lipinska, K, Terry, S, Tan, T Z, Lu, N, Trachsel-Moncho, L, Røsland, G V, Siraji, M I, Hellesøy, M, Rayford, A, Jacobsen, K, Ditzel, H J, Vintermyr, O K, Bivona, T G, Minna, J, Brekken, R A, Baguley, B, Micklem, D, Akslen, L A, Gausdal, G, Simonsen, A, Thiery, J P, Chouaib, S, Lorens, J B & Engelsen, A S T 2020, ' AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells ', Journal of Thoracic Oncology, vol. 15, no. 6, pp. 973-999 . https://doi.org/10.1016/j.jtho.2020.01.015
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 15, iss 6
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2020, 15, pp.973-999. ⟨10.1016/j.jtho.2020.01.015⟩
Lotsberg, M L, Wnuk-Lipinska, K, Terry, S, Tan, T Z, Lu, N, Trachsel-Moncho, L, Røsland, G V, Siraji, M I, Hellesøy, M, Rayford, A, Jacobsen, K, Ditzel, H J, Vintermyr, O K, Bivona, T G, Minna, J, Brekken, R A, Baguley, B, Micklem, D, Akslen, L A, Gausdal, G, Simonsen, A, Thiery, J P, Chouaib, S, Lorens, J B & Engelsen, A S T 2020, ' AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells ', Journal of Thoracic Oncology, vol. 15, no. 6, pp. 973-999 . https://doi.org/10.1016/j.jtho.2020.01.015
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 15, iss 6
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
IntroductionAcquired cancer therapy resistance evolves under selection pressure of immune surveillance and favors mechanisms that promote drug resistance through cell survival and immune evasion. AXL receptor tyrosine kinase is a mediator of cancer c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d993ac0309a0a7368f75b952f591d704
https://hal.archives-ouvertes.fr/hal-03490939
https://hal.archives-ouvertes.fr/hal-03490939
Autor:
Kirstine Jacobsen, Maarten L. Janmaat, Elke Gresnigt-van den Heuvel, Henrik J. Ditzel, Louise A. Koopman, Nora Pencheva, Esther C.W. Breij, Mikkel G. Terp, Marcel Brandhorst, Ulf Forssmann, Andreas Lingnau, Freddy De Bree, Paul W. H. I. Parren, Gijs G. Zom, Maria A. Zipeto
Publikováno v:
Koopman, L A, Terp, M G, Zom, G G, Janmaat, M L, Jacobsen, K, Van Den Heuvel, E G, Brandhorst, M, Forssmann, U, De Bree, F, Pencheva, N, Lingnau, A, Zipeto, M A, Parren, P W H I, Breij, E C W & Ditzel, H J 2019, ' Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer ', JCI Insight, vol. 4, no. 21, e128199 . https://doi.org/10.1172/jci.insight.128199
Targeted therapies and immunotherapy have shown promise in patients with non-small cell lung cancer (NSCLC). However, the majority of patients fail or become resistant to treatment, emphasizing the need for novel treatments. In this study, we confirm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70cd6b87fd8f3e4ecadf14c897d695a5
https://portal.findresearcher.sdu.dk/da/publications/dd6a54cd-c0ef-4dc9-92c5-d758d166510d
https://portal.findresearcher.sdu.dk/da/publications/dd6a54cd-c0ef-4dc9-92c5-d758d166510d
Autor:
Maria Lie Lotsberg, Camilla Krakstad, Kirstine Jacobsen, Jean Paul Thiery, Agnete S.T. Engelsen, Charlotte Kindt, Fredrik Hoel, Henrik J. Ditzel, Per Eystein Lønning, Stian Knappskog, James B. Lorens, Gro V. Røsland, Reham Helwa, Sissel E. Dyrstad, Karl Johan Tronstad, Tuan Zea Tan, Anna Berg, Deusdedit Tusubira, Ina Katrine Nitschke Pettersen, Ari Jon Arason
Publikováno v:
Cancer & Metabolism
Cancer & Metabolism, Vol 7, Iss 1, Pp 1-18 (2019)
Røsland, G V, Dyrstad, S E, Tusubira, D, Helwa, R, Tan, T Z, Lotsberg, M L, Pettersen, I K N, Berg, A, Kindt, C, Hoel, F, Jacobsen, K, Arason, A J, Engelsen, A S T, Ditzel, H J, Lønning, P E, Krakstad, C, Thiery, J P, Lorens, J B, Knappskog, S & Tronstad, K J 2019, ' Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC ', Cancer & Metabolism, vol. 7, 6 . https://doi.org/10.1186/s40170-019-0197-8
Cancer & Metabolism, Vol 7, Iss 1, Pp 1-18 (2019)
Røsland, G V, Dyrstad, S E, Tusubira, D, Helwa, R, Tan, T Z, Lotsberg, M L, Pettersen, I K N, Berg, A, Kindt, C, Hoel, F, Jacobsen, K, Arason, A J, Engelsen, A S T, Ditzel, H J, Lønning, P E, Krakstad, C, Thiery, J P, Lorens, J B, Knappskog, S & Tronstad, K J 2019, ' Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC ', Cancer & Metabolism, vol. 7, 6 . https://doi.org/10.1186/s40170-019-0197-8
Background Epithelial to mesenchymal transition (EMT) is a well-characterized process of cell plasticity that may involve metabolic rewiring. In cancer, EMT is associated with malignant progression, tumor heterogeneity, and therapy resistance. In thi
Publikováno v:
Cancer Research. 75:A2-59
Background: Erlotinib, an EGFR selective reversible inhibitor, has dramatically changed the treatment of non-small cell lung cancer (NSCLC) as approximately 70% of patients show significant tumor regression upon treatment. However, all patients event